A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors)

NCT00889382 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Solid Tumors

Interventions

DRUG: OSI-906
DRUG: Paclitaxel

Sponsor

Astellas Pharma Inc